Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that HER2-negative and PD-L1 (CPS) >= 5 status confers therapeutic sensitivity to Capecitabine, Nivolumab, Oxaliplatin in patients with Stomach Adenocarcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with fluoropyrimidine and platinum-based combination chemotherapy as a treatment option for the first-line treatment of adult patients with HER-2 negative advanced or metastatic gastric cancer (GC), gastroesophageal junction cancer (GEJC), or esophageal adenocarcinoma (EAC), whose tumours express PD-L1 (CPS) >= 5. This treatment regimen is specifically for nivolumab and XELOX (capecitabine and oxaliplatin) therapy, though the treatment regimen specifically notes that other evidence based platinum and fluoropyrimidine based regimens may be used as the EMA licensed indication does not define the platinum and fluoropyrimidine based chemotherapy.
This statement is based on a regulatory approval from the Health Service Executive:
Nivolumab in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER-2 negative advanced or metastatic gastric cancer (GC), gastroesophageal junction cancer (GEJC), or esophageal adenocarcinoma (EAC), whose tumours express PD-L1 (CPS) >= 5.